Clinical trials: High Risk Prostate Carcinoma
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart.
- Trial name
- NCT05665738
- Testing
- High Dose Rate Monotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Breast Carcinoma, Prostate Cancer Surgery
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease.
- Conditions
- Breast Carcinoma, Prostate Cancer Surgery, Thyroid Cancer, Parathyroid Adenomas
- Trial name
- NCT06835426
- Testing
- Single intravenous injection of the radiotracer, Imaging resected specimen using the high-resolution PET-CT specimen imager
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Algemeen Ziekenhuis Maria Middelares
Prostate Cancer
Evaluating Tolerability of ePUHRT With Brachytherapy Boost
The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external…
- Trial name
- NCT06817668
- Testing
- ePURT 5Gy x 5 fractions with single HDR boost of 15Gy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Indiana University
Prostate Cancer, Magnetic Resonance Imaging
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.
- Conditions
- Prostate Cancer, Magnetic Resonance Imaging, Population at Risk
- Trial name
- NCT05384535
- Testing
- Bi-parametric MRI
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northwell Health
Genitourinary Cancer, Adrenocortical Carcinoma
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare…
- Conditions
- Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract
- Trial name
- NCT03333616
- Testing
- Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will undergo external beam radiation therapy…
- Trial name
- NCT05477823
- Testing
- External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer, Oligometastasis
Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients
Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is focused on delaying progression rather than eliminating all tumor burden.
- Trial name
- OLIGOPELVIS2 (NCT03630666)
- Testing
- IADT, IADT + radiotherapy
- Where
- 16 sites in France
- Volunteers
- 256 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Cancer
Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate
In North America, around a quarter a million men are diagnosed with prostate cancer every year, and about 31,000 patients will die of their disease each year.
- Trial name
- NCT01444820
- Testing
- hypofractionation, conventional
- Where
- 12 sites in Canada
- Volunteers
- 329 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets
The goal of this clinical research study is find the highest tolerable dose of BMTP-11 when given to patients with prostate cancer that has spread. The safety of this drug will also be studied.
- Trial name
- NCT00872157
- Testing
- BMTP-11
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Adenocarcinoma
Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer
This study is a prospective, open label, single arm phase II trial. A total of 22 patients will be treated with atezolizumab, PROSTVAC, and pre-operative MVA-BN-Brachyury to confirm the efficacy of prostatic combination…
- Trial name
- AtezoVax (NCT04020094)
- Testing
- MVA-BN-Brachyury
- Where
- United States
- Sponsor
- University of Utah
Prostate Cancer, Prostate Cancer Adenocarcinoma
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
This is a prospective, randomized, open-label, phase II trial of cabozantinib in subjects with untreated, high risk prostate cancer undergoing radical prostatectomy. This multicenter study will enroll 30 subjects.
- Conditions
- Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
- Trial name
- SPARC (NCT03964337)
- Testing
- Cabozantinib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Prostate Cancer, Prostate Adenocarcinoma
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial.
- Trial name
- CAPTAIN (NCT05027477)
- Testing
- Radical Prostatectomy, TULSA Procedure
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 201 people
- Sponsor
- Profound Medical Inc.
Prostate Cancer, Radiotherapy Side Effect
Protons vs. Photons for High-risk Prostate Cancer
The purpose of this study is to assess late gastro-intestinal side-effects comparing proton therapy to photon therapy in high-risk prostate cancer patients receiving whole pelvic irradiation.
- Trial name
- NCT05350475
- Testing
- Proton therapy, Photon therapy
- Where
- 7 sites in Denmark
- Volunteers
- 102 people
- Sponsor
- University of Aarhus
Prostate Cancer
COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer
A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer.
- Trial name
- COAction (NCT06627530)
- Testing
- Darolutamide Oral Tablet, leuprorelin
- Where
- 6 sites in Brazil
- Volunteers
- 144 people
- Sponsor
- Brazilian Clinical Research Institute
Prostate Cancer
Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer
This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer.
- Trial name
- MOB-RT (NCT05313815)
- Testing
- Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of…
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT05946213
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 436 sites in United States, Canada and 3 more
- Volunteers
- 1,500 people
- Sponsor
- NRG Oncology
Prostate Cancer
Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy
This is a phase I study to evaluate the feasibility and safety of using MRI/MRS to identify the dominant intraprostatic lesion (DIL) and to selectively boost the lesion using inverse planned high dose rate (HDR) brachytherapy.
- Trial name
- NCT00807820
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Cancer of Prostate
Dynamic Focusing Evaluation for Prostate Cancer Treatment
Define the best acoustic parameters for the dynamic focusing HIFU transducer in the treatment of localized Prostate Cancer.
- Trial name
- FOC/DYN (NCT03632980)
- Testing
- "Ablatherm Foc/Dyn" or "Focal One" HIFU treatment
- Where
- France
- Volunteers
- 180 people
- Sponsor
- EDAP TMS S.A.
Prostate Cancer
Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)
BALANCE is a multicenter, prospective, randomized controlled trial enrolling men with unilateral high-risk localized prostate cancer identified by prostate biopsy, multiparametric MRI, and PSMA PET imaging.
- Trial name
- BALANCE (NCT07580196)
- Testing
- Unilateral Extended Pelvic Lymph Node Dissection, Bilateral Extended Pelvic Lymph Node Dissection
- Where
- 14 sites in Italy
- Volunteers
- 820 people
- Sponsor
- University of Turin, Italy